Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5, 2026 Altimmune, Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS, expectations were $-0.25. Operator: Good ...

Trauma healing shouldn't be a solo battle. Explore a three-level map: inner parts, relationships, and meaning, to know when ...

Q4 2025 Earnings Call March 5, 2026 4:30 PM ESTCompany ParticipantsAllan Kells - Vice President of Investor RelationsSean Duffy ...

AUSTIN, TX / ACCESS Newswire / March 2, 2026 / In modern metabolic medicine, few treatments have reshaped care like GLP-1 receptor agonists. If you are asking what is semaglutide, it is a prescription ...

Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi (R) for the treatment of adults with polycythemia vera (PV). The Company is seeking a ropeginterferon alfa-2b-njft label ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 3:10 PM ESTCompany ParticipantsLucas Montarce - Executive VP ...